Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 13;12(9):e063043.
doi: 10.1136/bmjopen-2022-063043.

Imaging timing after glioblastoma surgery (INTERVAL-GB): protocol for a UK and Ireland, multicentre retrospective cohort study

Collaborators, Affiliations

Imaging timing after glioblastoma surgery (INTERVAL-GB): protocol for a UK and Ireland, multicentre retrospective cohort study

Conor S Gillespie et al. BMJ Open. .

Abstract

Introduction: Glioblastoma is the most common malignant primary brain tumour with a median overall survival of 12-15 months (range 6-17 months), even with maximal treatment involving debulking neurosurgery and adjuvant concomitant chemoradiotherapy. The use of postoperative imaging to detect progression is of high importance to clinicians and patients, but currently, the optimal follow-up schedule is yet to be defined. It is also unclear how adhering to National Institute for Health and Care Excellence (NICE) guidelines-which are based on general consensus rather than evidence-affects patient outcomes such as progression-free and overall survival. The primary aim of this study is to assess MRI monitoring practice after surgery for glioblastoma, and to evaluate its association with patient outcomes.

Methods and analysis: ImagiNg Timing aftER surgery for glioblastoma: an eVALuation of practice in Great Britain and Ireland is a retrospective multicentre study that will include 450 patients with an operated glioblastoma, treated with any adjuvant therapy regimen in the UK and Ireland. Adult patients ≥18 years diagnosed with glioblastoma and undergoing surgery between 1 August 2018 and 1 February 2019 will be included. Clinical and radiological scanning data will be collected until the date of death or date of last known follow-up. Anonymised data will be uploaded to an online Castor database. Adherence to NICE guidelines and the effect of being concordant with NICE guidelines will be identified using descriptive statistics and Kaplan-Meier survival analysis.

Ethics and dissemination: Each participating centre is required to gain local institutional approval for data collection and sharing. Formal ethical approval is not required since this is a service evaluation. Results of the study will be reported through peer-reviewed presentations and articles, and will be disseminated to participating centres, patients and the public.

Keywords: NEUROSURGERY; Neurological oncology; Neuroradiology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Process of identifying a patient list at each collaborating neurosurgical unit. CNS, Central Nervous System; GB, Glioblastoma.
Figure 2
Figure 2
Bar chart representing pilot data compliance to NICE guidelines. NICE, National Institute for Health and Care Excellence.

References

    1. Ostrom QT, Patil N, Cioffi G, et al. . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 2020;22:iv1–96. 10.1093/neuonc/noaa200 - DOI - PMC - PubMed
    1. Philips A, Henshaw DL, Lamburn G, et al. . Brain tumours: rise in glioblastoma multiforme incidence in England 1995-2015 suggests an adverse environmental or lifestyle factor. J Environ Public Health 2018;2018:7910754. 10.1155/2018/7910754 - DOI - PMC - PubMed
    1. Poon MTC, Brennan PM, Jin K, et al. . Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? a population-based study in Wales (United Kingdom) and the United States. Neuro Oncol 2021;23:979–89. 10.1093/neuonc/noaa282 - DOI - PMC - PubMed
    1. Brodbelt A, Greenberg D, Winters T, et al. . Glioblastoma in England: 2007-2011. Eur J Cancer 2015;51:533–42. 10.1016/j.ejca.2014.12.014 - DOI - PubMed
    1. Zreik J, Moinuddin FM, Yolcu YU, et al. . Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the National cancer database from 2004 to 2013. J Neurooncol 2020;148:69–79. 10.1007/s11060-020-03469-w - DOI - PubMed

Publication types